<DOC>
	<DOCNO>NCT00683046</DOCNO>
	<brief_summary>Objectives : 1 . To evaluate disease free survival Campath 1H-based vivo T-cell depletion non-myelo-ablative ablative stem cell transplantation patient hematologic malignancy . 2 . To evaluate incidence severity acute chronic GVHD Campath 1H-based vivo T-cell depletion , patient hematologic malignancy undergo non-myelo-ablative stem cell transplantation . 3 . To evaluate engraftment chimerism Campath 1H-based vivo T-cell depletion non-myelo-ablative ablative stem cell transplantation patient hematologic malignancy .</brief_summary>
	<brief_title>T-Cell Depleted Allogeneic Stem Cell Transplantation Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Zubrod performance status 2 ( See Appendix B ) . Life expectancy severely limited concomitant illness . Adequate cardiac pulmonary function . Patients decrease LVEF PFTS evaluate cardiology pulmonary prior enrollment protocol . Serum creatinine &lt; 1.5 mg/dL Creatinine Clearance &gt; 50 ml/min . Serum bilirubin 2.0 mg/dl , SGPT &lt; 3 x upper limit normal No evidence chronic active hepatitis cirrhosis . HIVnegative Patient pregnant Patient guardian able sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsed refractory acute myelogenous lymphoid leukemia .</keyword>
	<keyword>Acute myeloid lymphocytic leukemia first remission high-risk recurrence.Chronic myelogenous leukemia accelerate phase blast-crisis .</keyword>
	<keyword>Chronic myelogenous leukemia chronic phase</keyword>
	<keyword>Chronic myelogenous leukemia accelerate phase blast-crisis</keyword>
	<keyword>Recurrent refractory malignant lymphoma Hodgkin 's disease .</keyword>
	<keyword>Chronic lymphocytic leukemia , relapse poor prognostic feature .</keyword>
	<keyword>Myeloproliferative disorder ( polycythemia vera , myelofibrosis ) poor prognostic feature .</keyword>
	<keyword>Severe aplastic anemia failure immunosuppressive therapy .</keyword>
	<keyword>Myelodysplastic syndrome ( include PNH )</keyword>
	<keyword>Multiple myeloma high risk disease recurrence .</keyword>
</DOC>